IEX •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 08/14/2026
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeIEX
Market Capitalization35.05 mln
Float26.32 mln
Earnings Date08/11/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-5.76
Highly reliable
Relative Strength
98
/ 100
Top performer
Debt / Equity
-0.95
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
BioXcel Therapeutics is a US-based drug development company that uses artificial intelligence to discover and advance treatments for brain disorders and cancer. Its approved product, IGALMI, is a dissolvable film placed under the tongue to rapidly calm agitation in adults with schizophrenia or bipolar disorder, while several related pipeline drugs aim to address agitation, apathy, and aggression in conditions such as Alzheimer's disease and dementia. The company is also advancing an oral cancer therapy targeting aggressive prostate, pancreatic, and other tumors by activating the body's innate immune response. Founded in 2017 and based in New Haven, Connecticut, BioXcel works alongside leading academic institutions including Columbia University and Yale University Medical School to support its research.
